Friday, April 1, 2022

Scientific consortium provides real-time risk assessment of SARS-CoV-2 variants on immune protection

A new program has been set up to provide a real-time risk assessment of variants of SARS-CoV-2, the virus that causes COVID-19. The program assesses how the variants might affect transmission, virulence, and resistance to both disease-induced (convalescent) and vaccine-induced immunity.

from Top Health News -- ScienceDaily https://ift.tt/O4agSyV
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

FDA clears IND for clinical trial testing switchable CAR-T therapy in patients with autoimmune diseases, without chemotherapy

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001...